cellestis vs slt, page-9

ForrestGump and Ridge,

Thanks so much for your info. I often see SLT being compared to market cap of CST to indicate where SLT can/should be. I now see that CST has far greater potential revenue than SLT in the short term, hence justifying its greater market cap.

As for SLT in a nutshell:
Specialise Hep A, E and C diagnostics with other vaccine related products in the pipeline. They have first rights to commercialise any technologies coming out of the famous Burnett Institute in Melbourne. (Burnett is the focal point in Aust. on infectious diseases).

Hep A and E rapid diagnostics are approved and ready to go commercial. Finger prrick and instant results with 97% accuracy vs 2 day pathology 60% accuracy, and it's cheap, makes it a unique and highly desirable product.

Hep E commercial deal with Genelabs has been announced and is expected to be finalised this month.

Hep A commercial deal - currently being evaluated by several companies from Europe, USA and Asia Pac. Expect to narrow down companies by end of 2003 and negotiate a deal by March 2004.

Hep C - in development. SLT have mentioned they expect to announce a collaboration deal with a multi-billion dollar bio in US to speed development.

Hep E deal worth approx 750K per year net.
Hep A deal expected 5x that.
Hep C with 170 million cases worldwide expects far more than HepE/A together. Expect 7-8 million per year.

All up, expect profits around 8-10 million per year ==> market cap potential of 150m, representing over 10 times current market cap of around 15m.

Also tightly held with only 21m tradeable shares. So could squeeze up (or down) on news.